ArticleClinical parkinsonism & related disorders2026
Patterns of weariness-related symptoms in Parkinson's disease: impact of disease progression and levodopa treatment.
Article in Clinical parkinsonism & related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Weariness-related symptoms (WRS), i.e. fatigue, daytime sleepiness, and sleep problems are common non-motor symptoms in Parkinson's disease (PD) that impair quality of life. Although related, they represent distinct clinical domains, and the role of dopaminergic therapy in their progression remains unclear. We compared stable levodopa regimens with levodopa dose escalation to evaluate their impact on WRS evolution. Methods: From a database of 1,521 PD patients, 159 individuals (mean age 64.7 ± 9.36 years; 61.7% male; Hoehn and Yahr stage 0-2) with two assessments 6-18 months apart were included. Patients were grouped into stable medication regimen (SMR) or increased levodopa dose (ILD). Longitudinal changes in fatigue, daytime sleepiness, and nighttime sleep problems were analyzed, including age-stratified comparisons. Results: In the SMR group, daytime sleepiness increased significantly over time (0.21 ± 0.86, P = 0.001), while fatigue and sleep problems remained stable. In contrast, the ILD group showed a significant increase in fatigue (0.15 ± 0.89, P = 0.017), with no changes in daytime sleepiness or sleep problems. Worsening daytime sleepiness under stable medication was confined to older patients (>65 years, P = 0.003), whereas fatigue worsening after levodopa escalation was mainly observed in younger patients (≤65 years, P = 0.03). Conclusion: Daytime sleepiness appears disease-driven and independent of medication changes, while fatigue is more closely associated with levodopa escalation, supporting individualized management and targeted therapeutic development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.